Europe’s Joint Clinical Assessment (JCA) is often framed as a major policy development: a single, shared clinical assessment intended to reduce duplication, simplify, and accelerate market access across the European Union (EU). For manufacturers navigating parallel submissions and repeated clinical debates, the appeal is obvious.

Yet beneath the promise of harmonization sits a more nuanced reality. Although the JCA will standardize elements of clinical evaluation, it will not standardize clinical judgments or create a unified approach to pricing and reimbursement. For many companies, the JCA is less a simplification than a structural change that introduces new strategic considerations.

Understanding what the JCA will and will not change has become a prerequisite for effective European launch planning.

What JCA actually changes

At its core, the JCA introduces a joint EU-level assessment of relative clinical effectiveness. In principle, this is intended to replace multiple national clinical reviews with a single European report, creating a common starting point for clinical discussions across markets.

For manufacturers, this represents a meaningful procedural shift. There will be one coordinated clinical submission, earlier visibility into cross-country clinical questions, and greater consistency in how core data are examined. Over time, this may reduce duplication and encourage more aligned evidence-generation strategies at the EU level.

However, the JCA report is best understood as a shared input, not a shared conclusion. Its influence will greatly depend on how national health technology assessment (HTA) bodies interpret and operationalize it.

One clinical report still leads to multiple clinical judgments

One of the most overlooked implications of the JCA is that a single clinical report does not align with how that evidence is interpreted across markets.

National HTA bodies will continue to apply their own methodological standards to the JCA output. Differences in accepted comparators, end point relevance, handling of indirect comparisons, and tolerance for uncertainty will persist even though the JCA is meant to address this by ensuring the scope covers the requests of all member states.

Context further complicates interpretation. Countries reimburse different products, use therapies across different populations, and position treatments differently within the care pathway.

As a result, the JCA does not eliminate divergence; it makes it more transparent. A shared assessment can expose the long-standing differences that drive variation in HTA outcomes across Europe.

Pricing and economics remain national, with important nuances

The JCA does not determine reimbursement, replace national economic assessments, or set prices. These decisions remain national by design.

That does not mean the JCA is commercially neutral. The joint assessment will comment on the strength, relevance, and uncertainty of the clinical evidence for each population, intervention, comparator, and outcome, a standardized framework used to define the JCA assessment scope and inform clinical evidence requirements. Those conclusions are likely to shape downstream negotiations and access discussions. Strong JCA outcomes can reinforce a manufacturer’s value story, whereas weaker or uncertain assessments may limit flexibility on both access and price and lead to the risk of pricing and market access delays.

Ultimately, national context remains decisive. Price-access trade-offs, budget impact thresholds, cost-effectiveness frameworks, pricing frameworks, and affordability constraints differ widely across Europe and across major evaluation archetypes.

A therapy viewed as bringing clinically appropriate evidence at the EU level may still face restricted access or downward price pressure in markets with tighter budgets or different system priorities.

National implementation will diverge

Early signals suggest that national implementation of the JCA will be uneven.

Some countries are positioning the JCA report as one input among several while maintaining established methodologies to assess clinical benefit and define access conditions. Germany and France, for instance, are expected to continue applying their own clinical frameworks, using the JCA to inform but not replace national judgments.

Smaller markets with more limited HTA resources may lean more heavily on the EU assessment. In markets such as Estonia, the EU JCA is likely to replace the clinical evaluation (where available) and to serve as the foundation for cost-effectiveness analysis, playing a direct role in national decision-making.

For manufacturers, this creates a fragmented transition landscape. Evidence expectations, timelines, and engagement models will differ by country, particularly in the early years. A single European clinical process does not remove the need for a market-by-market strategy. It increases the importance of understanding how each HTA body plans to use the JCA in practice.

The strategic implication: A dual market access model

The strategic takeaway for manufacturers is clear: Success under the JCA requires a dual approach.

At the EU level, companies must deliver robust, coherent, comparative clinical evidence that can withstand scrutiny under the EU JCA scientific methodology and translate into national clinical acceptance.

At the same time, national market access remains decisive. Value narratives, economic arguments, and pricing strategies must still be tailored to local comparators, clinical practice, and affordability constraints. The JCA does not replace national strategy. It raises expectations for how well EU-level evidence is translated into country-specific value stories.

Companies that treat the JCA as a compliance exercise rather than a strategic shift risk being caught between centralized evidence generation and decentralized decision-making.

Harmonization without simplification

The JCA marks a fundamental evolution in how clinical evidence is assessed in Europe, but it is not a shortcut to easier access or consistent pricing. It harmonizes process, not outcomes.

It is important to note that the JCA is only one year into implementation, and no JCA reports have yet been published. As national markets adapt to the JCA process while continuing to rely on existing national procedures, companies will need to closely monitor how the framework evolves and remain flexible in their approach. Based on extensive work with pharmaceutical and biotechnology companies on EU JCA readiness and decades of experience in European pricing and market access, one conclusion stands out: Success in the JCA era depends on mastering both the European narrative and the national reality.

Dmitry Goldenberg is a partner at Simon-Kucher, New York; Diane Cosset is a partner at Simon-Kucher, Paris; and Eleonora Sirena is a senior director at Simon-Kucher, Milan.

The authors would like to thank Zoe Yong and Scarlet Lausen-Kartal for their contributions to research and editorial support.